Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is very significant. They should have PR's this. Sometimes I don't know what the hell they are thinking over at Arrayit. The IR firm should pick up on this and create a PR.
Twitter is good for everyday mundane updates, but important development for a puclic company should be communicated via PR or other credible means. Get your crap together Arrayit!
I understand where you're coming from, but on the other had they just told you about conferences they are attending after they said the would last year. I would expect news about the CLIA certifications soon. That's what they are working on.
OvaDx will come in due time. It's no small feat.
At a time without funding they were able to conduct some studies to bring the test to the RUO stage.
Now with funding and better facilities to handle a larger workload they are working to bring the test from the research phase to the FDA filing stage, and ultimately the commercial stage. These things don't happen overnight.
In the past the share price has taken beatings to under 19 cents, and ever time I. Due time the share price has been a multi bagger, from my own experience I thought wise to just add as the price goes down because it always trends back up in due time. Now that the funding is in to actually realize the ambitions of OvaDx as a diagnostic, it should add very nicely to the value, once they announce anything significant to the progression of OvaDx.
We should see much better revenue this year. The real telling sign is events approaching the middle of the year.
You danced around my question.
So if I'd doesn't pertain to diagnostics you don't want to hear it?
Good news. I think it was the President of Arrayit that said they were attending more conferences this year. They have kept thier word and informed us via PR. I like that.
Very nice. A bright future indeed.
Maybe a five year old did pick the color.
I always listen to the ideas of my young nephews and nieces because a lot of times they are great ideas. I do not have children myself but if I did I would take their ideas to paint the headquarters of my company a particular color or design seriously.
California is know to have very interesting color schemes for architecture. I've been to the Bay Area many times and it's a beautiful place. Imagine if all companies built corporate headquarters in the same style and design, using the same colors, that would be extremely bland in my opinion. I'm glad Arrayit chose that color for their Brand new corporate headquarters that's larger than the previous building by over 5000 square feet.
Very nice and very professional. They are on their way to becoming a diagnostics company.
You seem pretty convinced and trying to create an illusion that Arrayit trying to bring their test to market will be this impossible feat because of FDA regulations that you yourself are not an expert in. I would suggest that you among the other board member seek clarification From Arrayit about the studies they plan to do and about the regulatory submission they plan to use.
There is a reason they are getting CLIA and ISO certifications for the laboratory.
The experts "DOCRO" is guiding them towards certification, conducting studies, and regulatory filing.
Also, ARRAYIT HAS BEEN IN COMMUNICATION WITH THE FDA AS TO THE REQUIREMENTS TO GARNER AND APPROVAL FOR OVADX.
All opinions welcome but the motives are clear.
Run up to the earning report. News shortly?
Good news today. Thanks ArrayIt. Keep us updated.
Good volume and nice movement up today. I am enjoying e view.
It's just funny to me. Seeing it over and over again over the years. I look and just laugh now. It's taught me a lot about penny stocks.
Someone's trying to take ARYC down. Haha.
You're right. I think ARYC CLIA and ISO certifications are positive moves in the right direction. Becoming a reference laboratory of diagnostics testing is a very important direction they are headed in.
Hearing news about commencing studies on OVaDx will be very credible. That will drive the price higher. They company has informed us that by mid year we can get to filing. So now would be the time to load up and just wait. It's a matter if you want to take the risk or not. I have taken the risk with a long term vision to where Arrayit can be as a diagnostics leader. So it really just come down to that. If you are an investor, then you either believe or not. If you are flipper, it can be shorted or traded through dips and spikes.
I think I hold a stock that is worth at least as much as EXAS or even VRML currently. So for me movements from 12 cents to 1 dollar are nothing, because I'm looking at the diagnostics future.
With the new headquarters, financing, certifications, and more transparency; I think they are headed there. It's no quick ride, but a long journey. Many companies have struggled in the past only to reap rewards multiple times greater than the investment put in. I think ARYC is going to be one of those stories.
Wow great movement today!
Thanks Bart. Whatever our investment strategy. We should be critical of everything when it comes to our money.
I actually sent a message to Mr. Nesbett about contacting Arrayit to create a pipeline page that displays the various diagnostics tests and where they are in development. Make it easy to guage the progress Arrayit is making on this front and a one stop page to find information related to the tests' information.
We are now down 50% since the high share price around November 11th 2013.
Should be hearing some nice news soon from the company.
The transparency through press release has been very good for the share price since 2013.
We are now down 50% since the high share price around November 11th 2013.
Should be hearing some nice news soon from the company.
The transparency through press release has been very good for the share price since 2013.
Promoting a company and products or future potential is not a bad thing. It is a positive strategy used by companies, and individuals to bring attention, investors, networking, etc...
http://www.thefreedictionary.com/hype
There has been no hype.
I have always thought that Arrayit should aggressively seek to be on the NASDAQ. They have the diagnostics arm that really can be their ticket there.
Will look into them. There is also a company called elite pharmaceutics that is working on an abuse deterrent technology. This is a very hot area right now because the potential revenue is in the hundreds of millions for the developer.
We'll see. Even at this price there is significant upside potential if Arrayit has positive developments with revenue, and OvaDx.
Hmm ArrayIt is continuing a low volume decline. This is a good buying opp.
Looks like we're headed down to mis December levels. A good buying opportunity approaches.
It's possible. At the market price.
True, if they get fast track. That would be great. I think they were originally targeting fast track approval.
I doubt a 2015 approval or even a decision.
An FDA filing would have a significant positive impact on share price, and this event is possibly within 6 months.
Great news
Nice volume today!
Thanks for the feedback guys. I need to look up a few things based on the info you gave me and see if taking a position possibly over 0.12 would be worth the long haul for a potential double in the future.
I really want to see what possibility of a buyout target they can be. That may be something to hold for a very pretty penny!
Happy New Year!
I'm waiting for further study results to be released for their abuse resistant tech, but I originally got in for the number of ANDAs they have in the pipeline. Just on that alone I was willing to purchase more.
Speculate what my trading "tactics" are, but I assure you, that you are incorrect. Check the two boards I moderate. I pick winners. In IPCI under $1.80, in ARYC under $0.15 This is my next winner, but I must make sure its worth it.
Thank you for your feedback.
That's actually a good point I didn't consider. Good trial results on their ART could present them as a good future buyout target. Interesting.
You may be right, but seriously, there are like 100 posts on this board everyday, and it's hard to follow with a life.
I try to view the posts, and most of them are not worth reading because they are usually one sided.
The longs versus shorts mentality is very evident here, but I want information and I try my best to be critical with my money.
As for seeking alpha. There are a lot of good articles and authors on there, but there are errors and they have agendas as well, so one must be critical of them too.
There probably are things I have missed, which is why I raised a concern on this board because I new the longs would be the ones to respond and give some good insight. After all everyone here seems to post immensely.
Right I saw that too, but do you think there is a link between that and the share structure. Wouldn't it benefit the company to reduce the number of outstanding shares considering the EPS is $0.02741 The stock could be valued properly and closer to a NASDAQ listing.
This is the most defensive board I have ever been on BTW. I appreciate it though.
This is what I saw in my brokerage account, which may not account for all transactions.
Date
Name-Position
Transaction
Shares
Price Range ($)
Shares Held
Mkt Value
12/2/13 Nigalaye Ashok G
Officer, Director and Ben... Sale 100,000 0.130 – 0.130 21,391,000 $12.5 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 100,000 0.130 – 0.130 71,303,500 $12.5 K
Epic Investments L ...
Beneficial Owner of more ... Sale 100,000 0.130 – 0.130 71,303,500 $12.5 K
11/26/13 Narine Jeenarine
Director and Beneficial O... Sale 298,626 0.120 – 0.130 21,578,700 $37.3 K
Nigalaye Ashok G
Officer, Director and Ben... Sale 298,626 0.120 – 0.130 21,301,500 $37.3 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 298,626 0.120 – 0.130 71,004,900 $37.3 K
Epic Investments L ...
Beneficial Owner of more ... Sale 298,626 0.120 – 0.130 71,004,900 $37.3 K
11/14/13 Narine Jeenarine
Director and Beneficial O... Sale 1,974,140 0.120 – 0.120 15,801,400 $230.9 K
Nigalaye Ashok G
Officer, Director and Ben... Sale 1,974,140 0.120 – 0.120 21,547,300 $230.8 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 1,974,140 0.120 – 0.120 71,824,500 $230.8 K
Epic Investments L ...
Beneficial Owner of more ... Sale 1,974,140 0.120 – 0.120 71,824,500 $230.8 K
11/11/13 Narine Jeenarine
Director and Beneficial O... Sale 421,000 0.120 – 0.120 21,666,400 $50.9 K
Nigalaye Ashok G
Officer, Director and Ben... Sale 421,000 0.120 – 0.120 21,421,000 $50.9 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 421,000 0.120 – 0.120 71,403,500 $50.9 K
Epic Investments L ...
Beneficial Owner of more ... Sale 421,000 0.120 – 0.120 71,403,500 $50.9 K
11/6/13 Narine Jeenarine
Director and Beneficial O... Sale 122,200 0.120 – 0.120 22,193,300 $15.1 K
Nigalaye Ashok G
Officer, Director and Ben... Sale 122,200 0.120 – 0.120 34,194,800 $15.1 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 122,200 0.120 – 0.120 73,798,600 $15.1 K
Epic Investments L ...
Beneficial Owner of more ... Sale 122,200 0.120 – 0.120 73,798,600 $15.1 K
10/28/13 Narine Jeenarine
Director and Beneficial O... Sale 204,820 0.010 – 0.130 22,220,200 $14.5 K
Date
Name-Position
Transaction
Shares
Price Range ($)
Shares Held
Mkt Value
10/28/13 Epic Pharma L L C
Beneficial Owner of more ... Sale 931,000 0.130 – 0.130 73,920,800 $119.4 K
Epic Investments L ...
Beneficial Owner of more ... Sale 931,000 0.130 – 0.130 73,920,800 $119.4 K
4/26/13 Nigalaye Ashok G
Officer, Director and Ben... Exercise of Options 8,230,450 0.020 – 0.020 16,999,100 $200.0 K
Epic Pharma L L C
Beneficial Owner of more ... Exercise of Options 8,230,450 0.020 – 0.020 9,399,710 $200.0 K
Epic Investments L ...
Beneficial Owner of more ... Exercise of Options 8,230,450 0.000 – 0.000 9,399,710 $0.0
Narine Jeenarine
Director and Beneficial O... Exercise of Options 8,230,450 0.020 – 0.020 15,357,300 $200.0 K
Potti Ram
Beneficial Owner of more ... Exercise of Options 8,230,450 0.020 – 0.020 15,626,900 $200.0 K
3/21/13 Narine Jeenarine
Director and Beneficial O... Exercise of Options 15,946,500 0.000 – 0.000 15,885,000 $0.0
Nigalaye Ashok G
Officer, Director and Ben... Exercise of Options 15,946,500 0.000 – 0.000 15,885,000 $0.0
Potti Ram
Beneficial Owner of more ... Exercise of Options 15,946,500 0.000 – 0.000 15,477,000 $0.0
Epic Pharma L L C
Beneficial Owner of more ... Exercise of Options 15,946,500 0.000 – 0.000 15,060,700 $0.0
Epic Investments L ...
Beneficial Owner of more ... Exercise of Options 15,946,500 0.000 – 0.000 15,060,700 $0.0
3/7/13 Dash Barry H
Director Award of Options 184,706 0.080 – 0.080 793,225 $14.8 K
Whitnell Jeffrey A
Director Award of Options 184,706 0.080 – 0.080 757,293 $14.8 K
Treppel Jerry I
Chief Executive Officer Award of Options 277,058 0.080 – 0.080 2,131,400 $22.2 K
Dick Christopher C
President Award of Options 230,882 0.080 – 0.080 1,166,730 $18.5 K
Narine Jeenarine
Director Award of Options 184,706 0.080 – 0.080 13,488,600 $14.8 K
Nigalaye Ashok G
Officer and Director Award of Options 184,706 0.080 – 0.080 13,488,600 $14.8 K
Potti Ram
Beneficial Owner of more ... Award of Options 184,706 0.080 – 0.080 13,080,600 $14.8 K
Ward Carter Julian
Chief Financial Officer Award of Options 230,882 0.080 – 0.080 1,900,440 $18.5 K
Potti Ram
Beneficial Owner of more ... Sale 356,700 0.090 – 0.090 12,895,900 $32.1 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 356,700 0.090 – 0.090 12,664,300 $32.1 K
Epic Investments L ...
Beneficial Owner of more ... Sale 356,700 0.090 – 0.090 12,664,300 $32.1 K
1/14/13 Narine Jeenarine
Director and Beneficial O... Exercise of Options 6,032,000 0.060 – 0.060 13,660,600 $377.0 K
Nigalaye Ashok G
Officer, Director and Ben... Exercise of Options 6,032,000 0.060 – 0.060 13,660,600 $377.0 K
Potti Ram
Beneficial Owner of more ... Exercise of Options 6,032,000 0.060 – 0.060 13,252,600 $377.0 K
Epic Pharma L L C
Beneficial Owner of more ... Exercise of Options 6,032,000 0.060 – 0.060 13,021,000 $377.0 K
Epic Investments L ...
Beneficial Owner of more ... Exercise of Options 6,032,000 0.060 – 0.060 13,021,000 $377.0 K
1/11/13 Narine Jeenarine
Director and Beneficial O... Sale 2,339,000 0.090 – 0.090 13,660,600 $211.9 K
Nigalaye Ashok G
Officer, Director and Ben... Sale 2,339,000 0.090 – 0.090 13,660,600 $211.9 K
Potti Ram
Beneficial Owner of more ... Sale 2,339,000 0.090 – 0.090 13,252,600 $211.9 K
Epic Pharma L L C
Beneficial Owner of more ... Sale 2,339,000 0.090 – 0.090 13,021,000 $211.9 K
Epic Investments L ...
Beneficial Owner of more ... Sale 2,339,000 0.090 – 0.090 13,021,000 $211.9 K